|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Secretory carcinoma (previously known as mammary analogue secretory carcinoma) is characterised by ETV6 rearrangements, most often ETV6-NTRK3 fusion.
|
30801752 |
2019 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mammary analogue secretory carcinoma (MASC) is a relatively recently described salivary gland adenocarcinoma characterized by ETV6-NTRK3 gene fusion and in most cases indolent clinical behavior.
|
31464708 |
2019 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study was based on a retrospective cohort study from 1993 to 2015 of patients whose sections were reviewed and who were newly diagnosed as having SC by the detection of ETV6 rearrangement.
|
30779892 |
2019 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we describe 2 cases of primary MASC in the sinonasal tract and provide a detailed clinical and histopathologic characterization of their morphology, immunohistochemical profile, and genetic background and highlight features allowing for its separation from its recently described molecular mimicker, ETV6-rearranged low-grade sinonasal adenocarcinoma.
|
29543674 |
2018 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mammary Analog Secretory Carcinoma With ETV6 Rearrangement Arising in the Conjunctiva and Eyelid.
|
29251639 |
2018 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In order to assess the frequency of variant NTRK3 fusions, and in particular whether the recently identified EML4-NTRK3 fusion is recurrent, 63 archival cases of infantile fibrosarcoma, congenital mesoblastic nephroma, mammary analog secretory carcinoma and secretory breast carcinoma (tumor types that are known to carry recurrent ETV6-NTRK3 fusions) were tested with NTRK3 break-apart FISH, EML4-NTRK3 dual fusion FISH, and targeted RNA sequencing.
|
29099503 |
2018 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
(Mammary analogue) secretory carcinoma harboring ETV6-NTRK3, and in rare cases ETV6-RET fusion, shares histomorphologic and immunophenotypical features with IC.
|
30045065 |
2018 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report a primary endobronchial tumor with histology, immunophenotype, and ETV6 rearrangement characteristic of MASC in a 62-year-old woman.
|
29104113 |
2018 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mammaglobin and ETV6 gene split detection could help to distinguish mammary analogue secretory carcinoma of salivary gland.
|
29752049 |
2018 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Positive immunostaining for S-100 protein and mammaglobin, followed by detection of ETV6 gene rearrangement by FISH and/or ETV6-NTRK3 fusion transcript by RT-PCR were used to identify MASCs.
|
28781197 |
2017 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ETV6 rearrangement in a case of mammary analogue secretory carcinoma of the skin.
|
27506949 |
2016 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In salivary gland tumor pathology, however, the ETV6-NTRK3 translocation is specific for mammary analogue secretory carcinoma (MASC), and has not been documented in any other salivary tumor type.
|
26492182 |
2016 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC).
|
26884591 |
2016 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland tumor that shares the same histologic appearance and ETV6 gene (12p13) rearrangement as secretory carcinoma of the breast.
|
27575269 |
2016 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mammary analog secretory carcinoma (MASC) is a recently recognized low-grade salivary carcinoma characterized by a specific ETV6 rearrangement.
|
26089091 |
2015 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mammary analogue secretory carcinoma (MASC) has a specific ETV6-NTRK3 translocation and morphologically overlaps with acinic cell carcinoma (AciCC).
|
25976476 |
2015 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Based on morphology and immunohistochemistry, cases suspicious for MASC were selected, and the diagnosis was confirmed by fluorescence in situ hybridization (FISH) for ETV6 rearrangement and by RT-PCR for the ETV6-NTRK3 fusion transcript.
|
25503077 |
2015 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mammary analogue secretory carcinoma (MASC) with an ETS variant gene 6 (ETV6)-neurotrophic tyrosine kinase receptor type 3 (NTRK3) translocation is a newly described type of salivary gland cancer.
|
26252941 |
2015 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All cases showed histopathologic findings compatible with those previously described for MASC and harbored an ETV6 split as visualized by fluorescence in situ hybridization.
|
25651470 |
2015 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers.
|
25456394 |
2015 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Aspiration cytologic findings of mammary analogue secretory carcinoma (MASC), a newly established salivary gland neoplasm defined by a t(12;15)(p13;q25) ETV6-NTRK3 translocation, are not fully characterized to date.
|
25087572 |
2015 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mammary analogue secretory carcinoma (MASC) is a recently described malignancy of the salivary glands characterized by an ETV6-NTRK3 (EN) fusion gene.
|
23955668 |
2014 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland neoplasm that is defined by ETV6-NTRK3 gene fusion.
|
24585770 |
2014 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although mammaglobin and S-100 positivity was seen in the majority of polymorphous low-grade adenocarcinomas and a minority of adenoid cystic carcinomas, none were positive for the ETV6 translocation characteristic of MASC.
|
24029710 |
2013 |
|
Mammary Analogue Secretory Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mammary analogue secretory carcinoma (MASC) is a recently described salivary gland neoplasm that is defined by ETV6-NTRK3 gene fusion.
|
23042752 |
2013 |